Phase II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Receptor-Positive or Her2/Neu-Positive Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2012
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 May 2009 Actual end date (1 Mar 2009) and actual patient number (70) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.